Newfeed

WUXI, China, Dec. 20, 2023 /PRNewswire/ — BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) in Ch

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: